NeuroBo Pharmaceuticals Price to Book Ratio 1970-1969 | MTVA
Historical price to book ratio values for NeuroBo Pharmaceuticals (MTVA) over the last 10 years. The current price to book ratio for NeuroBo Pharmaceuticals as of November 29, 2024 is 1.70.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| NeuroBo Pharmaceuticals Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.022B |
$0.000B |
|
NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.
|
